Phase Ib/II Study of Induction Chemotherapy and Durvalumab (MEDI4736) and Tremelimumab With Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 28 Feb 2024
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Capecitabine; Carboplatin; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2024 Results(n=16) studying efficacy of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma, presented at the 2024 Gastrointestinal Cancers Symposium
- 24 Aug 2023 Results (n=36) assessing safety and efficacy of adding the anti-PD-L1 antibody durvalumab to induction FOLFOX and preoperative chemotherapy in locally advanced esophageal adenocarcinoma published in the Annals of Surgery
- 07 Jun 2022 Results (n=36) of final analysis reporting efficacy and safety data presented at the 58th Annual Meeting of the American Society of Clinical Oncology